Signaling pathways in apoptosis as potential targets-for cancer therapy

被引：62

作者：

Huang, P ^{[1
]}

Oliff, A ^{[1
]}

机构：

[1] Dupont Merck Pharmaceut Co, Glenolden, PA 19036 USA

来源：

TRENDS IN CELL BIOLOGY | 2001年 / 11卷 / 08期

关键词：

D O I：

10.1016/S0962-8924(01)02063-3

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Genetic instability contributes to the origin of cancer as well as to the ability of cancer cells to become resistant to various therapies. Because of this, cytotoxic rather than cytostatic therapies might be most effective against this disease. Many oncogenes and tumor suppressors mediate their effects by interfering with or inducing apoptotic signaling. Thus, apoptotic pathways might be significantly altered in cancer cells relative to untransformed cells, and these differences might present a therapeutic window that can be exploited for development of cancer drugs.

引用

收藏

页码：343 / +

页数：4

相关论文

共 62 条

[31]

Li J, 1998, CANCER RES, V58, P5667

[32] The mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells [J].

Matsuyama, S ;

Xu, QL ;

Velours, J ;

Reed, JC .

MOLECULAR CELL, 1998, 1 (03) :327-336

[33] Nuclear and mitochondrial apoptotic pathways of p53 [J].

Moll, UM ;

Zaika, A .

FEBS LETTERS, 2001, 493 (2-3) :65-69

[34] Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis [J].

Nesterov, A ;

Lu, XJ ;

Johnson, M ;

Miller, GJ ;

Ivashchenko, Y ;

Kraft, AS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :10767-10774

[35] Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies [J].

Petros, AM ;

Nettesheim, DG ;

Wang, Y ;

Olejniczak, ET ;

Meadows, RP ;

Mack, J ;

Swift, K ;

Matayoshi, ED ;

Zhang, HC ;

Thompson, CB ;

Fesik, SW .

PROTEIN SCIENCE, 2000, 9 (12) :2528-2534

[36] Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology [J].

Plas, DR ;

Talapatra, S ;

Edinger, AL ;

Rathmell, JC ;

Thompson, CB .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :12041-12048

[37] Structural basis for the inhibition of caspase-3 by XIAP [J].

Riedl, SJ ;

Renatus, M ;

Schwarzenbacher, R ;

Zhou, Q ;

Sun, CH ;

Fesik, SW ;

Liddington, RC ;

Salvesen, GS .

CELL, 2001, 104 (05) :791-800

[38] Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis [J].

Sabbatini, P ;

McCormick, F .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (34) :24263-24269

[39] Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis [J].

Sattler, M ;

Liang, H ;

Nettesheim, D ;

Meadows, RP ;

Harlan, JE ;

Eberstadt, M ;

Yoon, HS ;

Shuker, SB ;

Chang, BS ;

Minn, AJ ;

Thompson, CB ;

Fesik, SW .

SCIENCE, 1997, 275 (5302) :983-986

[40] Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms [J].

Sausville, EA ;

Arbuck, SG ;

Messmann, R ;

Headlee, D ;

Bauer, KS ;

Lush, RM ;

Murgo, A ;

Figg, WD ;

Lahusen, T ;

Jaken, S ;

Jing, XX ;

Roberge, M ;

Fuse, E ;

Kuwabara, T ;

Senderowicz, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2319-2333

← 1 2 3 4 5 6 7 →